Sarepta Therapeutics (SRPT) Is Up 16.3% After Early siRNA Muscle Data Validates Avß6 Platform
Sarepta Therapeutics saw a 16.3% surge after reporting positive early Phase 1/2 data for its SRP-1001 and SRP-1003 siRNA programs, demonstrating dose-dependent muscle exposure and favorable tolerability. These results validate its Avβ6 integrin-targeted delivery platform, strengthening its broader siRNA pipeline for neuromuscular and neurodegenerative conditions. However, the company's near-term investor sentiment and revenue remain heavily tied to its ELEVIDYS gene therapy's safety, regulatory approval, and operational throughput, with ongoing concerns about liver injury risk in Duchenne patients.
Aberdeen Group Boosts Stake in Sarepta Therapeutics
Aberdeen Group plc, a major institutional investor, increased its stake in Sarepta Therapeutics (NASDAQ:SRPT) by 13.6% in the fourth quarter of 2025. This move signals continued institutional confidence in the biotech firm's pipeline of precision genetic medicines for rare neuromuscular diseases. Other hedge funds also boosted their positions, reinforcing the positive outlook for Sarepta Therapeutics.
SG Americas Securities Trims Sarepta Therapeutics Stake
SG Americas Securities LLC has significantly reduced its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 62.8% in the fourth quarter of 2025, according to a recent 13F filing. The firm now owns 191,371 shares, valued at $4.1 million, down from 514,151 shares. This move highlights a shift in investor sentiment towards the biotech company, which specializes in genetic medicines for rare neuromuscular diseases.
SG Americas Securities LLC Lowers Holdings in Sarepta Therapeutics, Inc. $SRPT
SG Americas Securities LLC significantly reduced its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 62.8% in the fourth quarter, selling 322,780 shares to hold 191,371 shares valued at $4.12 million. The move follows Sarepta reporting a substantial quarterly loss of $3.58 EPS and a 32.7% year-over-year revenue decline, coupled with a negative net margin of 38.3%. Despite the stock's market cap of $2.44 billion, it carries a "Hold" consensus rating with a $32.59 average target price from analysts, reflecting diverse opinions including nine "Buy," thirteen "Hold," and six "Sell" ratings.
The Precedent: Federal Circuit Upholds Gene Therapy Host Cell Claims Under 35 U.S.C. § 101 in Regenxbio Inc., Et Al. v. Sarepta Therapeutics, Inc., Et Al.
The Federal Circuit reversed a district court's summary judgment, ruling that gene therapy host cell claims in Regenxbio Inc., et al. v. Sarepta Therapeutics, Inc., et al. are patent-eligible under 35 U.S.C. § 101. The court determined that the claimed host cells, containing recombinant nucleic acid molecules, are "markedly different" from anything found in nature, aligning with the Chakrabarty decision. This ruling emphasizes that human-engineered biological inventions incorporating naturally occurring sequences can be patent-eligible if the composition as a whole is nonnaturally occurring and possesses distinct characteristics and utility.
Wealth Enhancement Advisory Services LLC Acquires 62,981 Shares of Sarepta Therapeutics, Inc. $SRPT
Wealth Enhancement Advisory Services LLC significantly increased its stake in Sarepta Therapeutics by 143.9% in Q4 2025, now holding 106,759 shares valued at $2.41 million. This comes despite Sarepta missing Q4 earnings estimates, reporting ($3.58) EPS against a ($0.87) consensus. The article also notes recent insider selling by Director Stephen Mayo and that institutional investors own 86.68% of the company's stock.
Why is Sarepta Therapeutics (SRPT) up 24.2% since last earnings report?
This article analyzes why Sarepta Therapeutics (SRPT) has seen a 24.2% increase in its stock price since its last earnings report. It highlights strong market performance following the report. Further details within the article likely delve into specific reasons for this growth.
Sarepta gains on data for muscular dystrophy therapies
The article reports that Sarepta Therapeutics' stock saw gains following the release of new data regarding its muscular dystrophy therapies. This positive development likely influenced investor confidence and market performance for the company.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. announced that it granted equity awards consisting of 113,855 restricted stock units (RSUs) to 24 new employees hired in the first quarter of 2026. These awards were approved by the Compensation Committee and are considered a material inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with one-fourth vesting each year, contingent on continued employment.
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Swings
Sarepta Therapeutics (SRPT) has seen recent share price gains of 13% over the past week and 19% over the past month, contrasting with a 68.7% decline over the last year. The stock is currently trading at US$19.97, with a consensus analyst price target of US$20.61, indicating it is slightly undervalued. However, while some metrics suggest a discount, others point to the stock being expensive, raising questions about whether the discount is a genuine opportunity or a reflection of underlying business risks, particularly concerning ELEVIDYS safety and high costs.
Sarepta plans FDA filings seeking full approval for two DMD therapies
Sarepta Therapeutics is preparing to submit applications to the FDA for full approval of its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys, and drug, Amondys 45. The company will use data from previous trials for both submissions. Elevidys received accelerated approval in 2023, and Amondys 45 is a treatment for patients with a specific gene mutation.
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance
The SPDR S&P Biotech ETF (XBI), which holds 150+ equally weighted positions, is currently facing headwinds due to FDA staffing cuts that could slow regulatory approvals, impacting biotech valuations. The performance of XBI in 2026 will largely depend on key phase 3 data readouts from major holdings like Moderna (MRNA), Krystal Biotech (KRYS), and Sarepta Therapeutics (SRPT), alongside the FDA's operational capacity under new leadership. The fund's equal-weight structure means that individual clinical trial successes or failures, as well as the FDA's approval pace, will significantly influence XBI's overall direction, amplifying both gains and losses.
Massachusetts Biotech Co. Finds High-Potential Muscle Treatment Breakthrough
Sarepta Therapeutics Inc. (SRPT:NASDAQ), a Massachusetts-based biotech company, has announced promising early clinical trial results for investigational treatments SRP-1001 and SRP-1003, targeting facioscapulohumeral muscular dystrophy (FSHD) and myotonic dystrophy type 1 (DM1) respectively. These early results show significant biomarker reductions and dose-dependent drug exposure, suggesting high potential for these severe and currently untreatable diseases. Despite varying analyst ratings following the news, the company's shares have rebounded, highlighting investor interest in their siRNA platform after previous setbacks with gene therapies.
Mirador Capital Partners LP Invests $3.01 Million in Sarepta Therapeutics, Inc. $SRPT
Mirador Capital Partners LP recently invested $3.01 million in Sarepta Therapeutics, acquiring 139,982 shares, representing about 0.13% of the company. Despite a significant EPS miss and mixed market sentiment, analysts maintain a "Hold" rating with an average target of $32.30, while institutional investors show varying activity and a director recently sold shares. The biotechnology company, focused on genetic medicines for rare neuromuscular diseases, recently saw its stock drop 42% on fatalities and reported a negative net margin.
Could Sarepta Therapeutics’ (SRPT) New siRNA Data Mark a Turning Point Beyond Duchenne Therapies?
Sarepta Therapeutics recently reported positive early human data from its SRP-1001 and SRP-1003 siRNA programs, demonstrating dose-dependent muscle exposure and target knockdown, suggesting potential expansion beyond its Duchenne therapies. While this data reinforces the company's long-term diversification strategy, the short-term focus remains on managing ELEVIDYS safety concerns and achieving traditional approvals for its Duchenne treatments. Investors should consider these factors as well as analyst forecasts, which project significant revenue changes and offer varying fair value estimates for SRPT.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Recommendation of "Hold" by Brokerages
Sarepta Therapeutics (NASDAQ:SRPT) has received a consensus "Hold" rating from twenty-eight brokerages, with an average 12-month price target of $32.30. Despite a recent rally driven by positive early-phase clinical data and significant call buying, the company reported a substantial EPS miss and a 32.7% year-over-year revenue decline. Mixed signals also come from insider activity, with a director selling shares while institutional investors increased their holdings.
Sarepta Therapeutics - It's Too Early To Get Excited About siRNA Data (NASDAQ:SRPT)
Sarepta Therapeutics' stock surged on early promising siRNA data for neuromuscular diseases, but the author remains cautious. While SRP-1001 and SRP-1003 showed strong target engagement and safety, their clinical efficacy in patient outcomes is not yet proven. The company also faces challenges including safety concerns with other therapies, competitive pressures, and leadership changes, leading the author to recommend staying on the sidelines until late-stage efficacy data is available.
Sarepta Therapeutics shares rise on early promise for rare disease drugs
Sarepta Therapeutics' shares rose by about 35% after the company released promising early data for two new rare disease drugs, SRP-1001 and SRP-1003. These treatments are for different forms of muscular dystrophy and appear to be safe and effective in early clinical trials, offering a potential path forward for the company after a turbulent previous year. While data is preliminary and further studies are needed, the results signal a positive direction for Sarepta's pipeline.
Sarepta sees early success with RNAi drugs from Arrowhead
Sarepta Therapeutics' shares surged after announcing promising early clinical data for two RNAi drugs, SRP-1001 and SRP-1003, acquired from Arrowhead Pharmaceuticals. These experimental therapies aim to treat rare muscle-weakening conditions by delivering small interfering RNA to target genetic abnormalities, showing high muscle concentrations without severe side effects in Phase 1/2 studies. The positive results validate Sarepta's significant investment in Arrowhead's platform amidst recent setbacks and leadership changes within the company.
Sarepta Pushes Past Gene Therapy Debacle as RNA Therapies Show Early Promise
Sarepta Therapeutics has seen its stock jump after unveiling promising early biomarker data for two RNA interference assets, SRP-1001 and SRP-1003, licensed from Arrowhead Pharmaceuticals. These developments mark a strategic pivot away from gene therapies that were associated with patient deaths and a significant drop in Sarepta's valuation. Analysts predict over $1 billion in peak sales for each of these RNA programs, which target facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1, respectively.
Sarepta Surges As It Looks To Take On Novartis' $12 Billion Deal
Sarepta Therapeutics' stock surged after reporting promising results for its gene-silencing technology in two forms of muscular dystrophy, FSHD1 and DM1, challenging Novartis' major acquisition in the space. These initial findings from Sarepta's siRNA platform indicate significant potential for its new drug developments. The positive news spurred investor interest, positioning Sarepta as a competitor in the muscular dystrophy treatment market.
Sarepta's big bet on Arrowhead's siRNA assets yields early data
Sarepta Therapeutics has released initial clinical data for two siRNA candidates, SRP-1001 for FSHD1 and SRP-1003 for DM1, acquired from Arrowhead Pharmaceuticals. The data from single-dose phase 1/2 trials suggest the technology effectively delivers the construct into muscle and has shown promising suppression of target genes. These early results are critical for Sarepta, as analysts view the siRNA programs as vital to the company's future amidst challenges to its core business.
SRPT Stock Rallies After Promising Early Results For RNA Therapies Targeting Rare Muscle Diseases
Sarepta Therapeutics Inc. (SRPT) released encouraging initial results from early trials of two investigational RNA therapies, SRP-1001 and SRP-1003, for facioscapulohumeral muscular dystrophy type 1 and myotonic dystrophy type 1. The company reported promising safety and biological activity, suggesting a breakthrough in overcoming delivery challenges for RNA therapies. Following this positive update, Sarepta's stock saw over a 3% increase in premarket trading.
Sarepta Therapeutics’ experimental siRNA therapies show promising early results
Sarepta Therapeutics' shares jumped significantly after the company released positive early clinical results from two investigational siRNA therapies for neuromuscular diseases, SRP-1001 and SRP-1003. The studies demonstrated dose-dependent muscle exposure, favorable tolerability, and proof that a single dose can reduce target protein or mRNA levels. Analysts highlight the potential for these results to de-risk Sarepta's broader siRNA platform and help diversify its portfolio beyond Duchenne muscular dystrophy.
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
Sarepta Therapeutics announced early clinical data from its siRNA programs for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and myotonic dystrophy type 1 (DM1). The results showed dose-dependent muscle exposure, early biomarker effects, and favorable tolerability for SRP-1001 and SRP-1003, indicating high muscle concentrations without dose-limiting toxicity. This reinforces confidence in their αvβ6 integrin-targeted delivery platform and its potential to significantly alter the treatment landscape for these rare genetic diseases.
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
Sarepta Therapeutics, Inc. announced it will host a webcast and conference call on March 25, 2026, at 8:30 am ET to present early clinical results from its Phase 1/2 studies. The data will cover SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1). The event will be accessible via Sarepta's investor relations website, with registration required for phone participation.
Sarepta plans to seek full FDA approval of 2 Duchenne treatments
Sarepta Therapeutics plans to seek full FDA approval for its Duchenne muscular dystrophy treatments, Amondys 45 and Vyondys 53, both exon-skipping therapies currently under accelerated approval. The company intends to submit applications by the end of April, incorporating clinical trial data from the ESSENCE study and real-world evidence. This move comes despite the ESSENCE trial's primary endpoint not achieving statistical significance, with Sarepta arguing for the clinical meaningfulness of the improvements and the positive safety profile.
A Look At Sarepta Therapeutics (SRPT) Valuation After Fresh FDA Feedback And ELEVIDYS Safety Study Update
Sarepta Therapeutics (SRPT) has received positive FDA feedback for its supplemental applications for AMONDYS 45 and VYONDYS 53, and has new enrollment activity in its ELEVIDYS ENDEAVOR Cohort 8 safety study. Despite these clinical updates, the company's share price has experienced significant declines recently. Simply Wall St's analysis suggests Sarepta is undervalued with a fair value of $20.35 against a last close of $16.69, though this valuation is subject to risks like ELEVIDYS safety concerns and competitive pressures.
How Investors Are Reacting To Sarepta Therapeutics (SRPT) Pushing Duchenne Drugs Toward Full FDA Approval
Sarepta Therapeutics plans to seek full FDA approvals for its Duchenne muscular dystrophy exon-skipping drugs, AMONDYS 45 and VYONDYS 53, by the end of April. This move is significant for the long-term stability of Sarepta's Duchenne franchise. The company's investment narrative heavily relies on the success and safety of both its gene therapy, ELEVIDYS, and the exon-skipping drugs, with safety concerns around ELEVIDYS posing a key risk for investors.
How Investors Are Reacting To Sarepta Therapeutics (SRPT) Pushing Duchenne Drugs Toward Full FDA Approval
Sarepta Therapeutics (SRPT) plans to file by April to convert accelerated FDA approvals for its Duchenne muscular dystrophy exon-skipping drugs, AMONDYS 45 and VYONDYS 53, to traditional approvals. This move, leveraging Phase 3 data and real-world evidence, is crucial for the longevity of Sarepta's Duchenne franchise. However, investor focus remains on the safety, site capacity, and patient uptake of its ELEVIDYS gene therapy, especially after recent safety concerns and a reported fatality, with analysts modeling varied revenue and earnings scenarios for the company.
How Investors Are Reacting To Sarepta Therapeutics (SRPT) Pushing Duchenne Drugs Toward Full FDA Approval
Sarepta Therapeutics (SRPT) plans to file by April's end for full FDA approvals for its Duchenne muscular dystrophy drugs AMONDYS 45 and VYONDYS 53, transitioning from accelerated to traditional approval using Phase 3 data. This move aims to strengthen its Duchenne franchise, complementing its ELEVIDYS gene therapy, although ELEVIDYS still faces significant safety and regulatory scrutiny. The company forecasts substantial revenue and earnings growth despite a projected yearly revenue decline.
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
Sarepta Therapeutics announced its intention to submit supplemental new drug applications (sNDAs) to the FDA by the end of April 2026 for AMONDYS 45® and VYONDYS 53®, seeking conversion from accelerated to traditional approval. This decision follows FDA feedback and is supported by data from the ESSENCE confirmatory study and substantial real-world evidence, which addresses the challenges of demonstrating functional changes over long periods in rare diseases like Duchenne muscular dystrophy. Despite the ESSENCE study's primary endpoint not meeting statistical significance, an updated analysis and favorable safety profiles bolster Sarepta's case for traditional approval.
Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs
Sarepta Therapeutics plans to submit supplemental new drug applications to the FDA by the end of April, seeking traditional approvals for its Duchenne muscular dystrophy drugs, AMONDYS 45 and VYONDYS 53. The company will use ESSENCE data and real-world evidence, despite the ESSENCE study's primary endpoint not reaching statistical significance, partly due to COVID-19's impact. Sarepta's stock performance shows a bearish trend, with a neutral RSI and bullish MACD indicating mixed momentum, and analysts holding a "Hold" rating with an average price target of $21.29.
Oppenheimer Reiterates "Outperform" Rating for Sarepta Therapeutics (SRPT) | SRPT Stock News
Oppenheimer has reiterated its "Outperform" rating for Sarepta Therapeutics (SRPT), maintaining a price target of $37.00 USD. This comes amidst varying analyst opinions, with some firms raising price targets while others maintain "Sell" ratings or have lowered targets. Wall Street analysts currently project an average target price of $29.68 for SRPT, suggesting potential upside, while GuruFocus estimates a significantly higher fair value.
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure
Sarepta Therapeutics plans to pursue traditional FDA approval for its Duchenne muscular dystrophy exon skippers, Amondys 45 and Vyondys 53, despite the treatments failing their confirmatory trials. The company will submit additional data, including real-world evidence and re-evaluated trial data, to support its case for sustained market presence. This decision comes during a challenging period for Sarepta, marked by leadership changes and regulatory scrutiny of its gene therapy products.
Sarepta Therapeutics (NASDAQ:SRPT) Earns Outperform Rating from Oppenheimer
Oppenheimer has reissued an "Outperform" rating for Sarepta Therapeutics (NASDAQ:SRPT), setting a price target of $37.00, which suggests a significant upside of 117% despite mixed analyst ratings and the stock's recent decline. This comes after Sarepta reported a substantial EPS miss and a 32.7% decrease in revenue year-over-year. The biotechnology company, specializing in genetic medicines for rare neuromuscular diseases, continues to face profitability challenges, with insiders recently selling shares.
Has Sarepta Therapeutics (SRPT) Fallen Too Far After A 77% One-Year Share Price Drop?
Sarepta Therapeutics (SRPT) has experienced a significant 77% share price drop over the last year, leading to questions about its current valuation. Despite the sharp decline, a Discounted Cash Flow (DCF) analysis suggests the stock is 78.2% undervalued, projecting an intrinsic value of $77.20 per share against its current price of $16.84. However, its Price-to-Sales (P/S) ratio of 0.80x is in line with Simply Wall St's proprietary Fair Ratio of 0.78x, indicating it might be 'about right' based on revenue metrics.
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study
Sarepta Therapeutics (SRPT) shares rose after the company announced the start of screening and enrollment for cohort 8 of its phase Ib ENDEAVOR study. This cohort aims to improve the safety profile of its DMD gene therapy, Elevidys, in non-ambulatory patients by using an enhanced sirolimus-based immunosuppressive regimen. The study seeks to determine if pre- or post-infusion sirolimus can reduce acute liver complications, following prior patient deaths linked to liver failure from Sarepta's gene therapies, which led to significant FDA label changes for Elevidys.
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
Sarepta Therapeutics has initiated screening and enrollment for Cohort 8 of its ENDEAVOR study, aiming to evaluate an enhanced immunosuppression regimen using sirolimus with ELEVIDYS gene therapy for non-ambulant Duchenne muscular dystrophy patients. This cohort, involving approximately 25 participants, seeks to mitigate the risk of acute liver injury associated with AAV gene therapy, building on existing dystrophin expression data and clinical experience. ELEVIDYS is currently the only approved gene therapy for Duchenne, having treated over 1,200 patients globally.
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study
Sarepta Therapeutics' shares rose after the company announced it began screening and enrollment for a study cohort to enhance the safety protocol of its gene therapy, Elevidys, for non-ambulant Duchenne muscular dystrophy patients. The study will investigate if administering sirolimus before and after Elevidys infusion can reduce risks of acute liver injury and failure. This comes after Elevidys faced scrutiny last year regarding liver issues and patient deaths, especially for non-ambulant patients who were put on hold temporarily.
Extra immune drug tested to limit liver damage in Duchenne gene therapy trial
Sarepta Therapeutics has initiated enrollment for Cohort 8 of its ENDEAVOR study, which will evaluate an enhanced immunosuppression regimen using sirolimus with ELEVIDYS gene therapy for non-ambulatory individuals with Duchenne muscular dystrophy. This cohort aims to mitigate the risk of acute liver injury associated with AAV gene therapy by administering sirolimus before and after ELEVIDYS infusion. The study will enroll approximately 25 participants to assess the incidence of acute liver injury and ELEVIDYS-dystrophin expression.
Price-Driven Insight from (SRPT) for Rule-Based Strategy
This article provides a price-driven insight into Sarepta Therapeutics Inc. (SRPT) for rule-based trading, indicating a near-term neutral sentiment amidst mid and long-term weakness. It highlights an exceptional risk-reward short setup and outlines three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis. The report suggests a potential pause in the stock's weakness with specific entry zones, targets, and stop losses.
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness
Sarepta Therapeutics (SRPT) has experienced significant share price volatility, with a 23% decline over the past three months despite a positive 1-year return. Analysts view the company as undervalued with a fair value of $20.35 against a current price of $16.40, driven by expectations of future earnings growth and improving margins, though concerns remain regarding drug safety and competition. Investors are encouraged to consider both the company's potential and risks before making investment decisions.
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness
Sarepta Therapeutics (SRPT) has experienced significant share price weakness, with a 23% decline over the past three months, despite analysts suggesting it is undervalued. The company's valuation narrative points to a fair value of $20.35 against its last close of $16.40, with analyst consensus price targets up to $23.96. However, concerns such as safety scrutiny for its drug Elevidys and competition for exon-skipping drugs introduce swing factors that investors need to consider.
Union Square Park Capital Management LLC Makes New Investment in Sarepta Therapeutics, Inc. $SRPT
Union Square Park Capital Management LLC has made a new investment in Sarepta Therapeutics, acquiring 105,000 shares worth approximately $2.02 million in the third quarter. This investment comes despite Sarepta reporting a significant earnings miss and a revenue decrease of 32.7% year-over-year. The biotechnology company has a mixed analyst sentiment with an average "Hold" rating and an average price target of $32.15, while institutional ownership remains high at 86.68%.
Quinn Opportunity Partners LLC Increases Stake in Sarepta Therapeutics, Inc. $SRPT
Quinn Opportunity Partners LLC significantly increased its stake in Sarepta Therapeutics, Inc. by 29.9% in Q3, now owning 0.39% of the company's shares. Other institutional investors like Invesco Ltd. and Connor Clark & Lunn Investment Management Ltd. also augmented their positions, leading to institutional investors holding 86.68% of the company's stock. Sarepta Therapeutics reported a wider-than-expected EPS loss in its recent earnings but surpassed revenue estimates, while the stock currently carries a consensus "Hold" rating with a target price of $32.15.
Sarepta (SRPT) executive has shares withheld to pay RSU tax
Louise Rodino-Klapac, President of R&D and Tech Ops at Sarepta Therapeutics, Inc. (SRPT), had 948 shares of common stock withheld on March 11, 2026, totaling $17.03 per share, to cover tax obligations from vested restricted stock units. This transaction was a routine adjustment related to equity compensation and not an open-market trade. After the withholding, she directly holds 225,323 shares of Sarepta common stock.
Tax withholding trims Sarepta (NASDAQ: SRPT) EVP's stock stake
Sarepta Therapeutics' EVP and General Counsel, Cristin Rothfuss, had 974 shares of common stock withheld by the company to cover tax obligations. This transaction, which occurred on March 11, 2026, was related to restricted stock units that vested on March 10, 2025. After the withholding, Rothfuss still directly holds 137,544 shares, indicating that this was a tax-related disposition and not an open-market sale.
Sarepta (SRPT) CFO has 256 shares withheld to cover RSU taxes
Sarepta Therapeutics, Inc. (SRPT) Chief Financial Officer Ryan Ho-Yan Wong had 256 shares withheld by the company to cover taxes on restricted stock units that vested from a grant dated March 10, 2025. This disposition on March 11, valued at $17.03 per share, is a routine tax-withholding event and not an open-market sale. After this transaction, Wong directly holds 135,064 shares of Sarepta common stock.
Is Sarepta Therapeutics (SRPT) A Potential Opportunity After An 84% One-Year Share Price Fall
Sarepta Therapeutics (SRPT) has experienced an 84% share price decline over the past year, prompting an analysis of its valuation. Despite the significant drop, a Discounted Cash Flow (DCF) analysis suggests the stock is currently undervalued by 78.2% with an intrinsic value of $76.57 per share, while its Price-to-Sales (P/S) ratio of 0.80x indicates it is "about right" when compared to its proprietary Fair Ratio. The article encourages investors to explore different valuation narratives and emphasizes the importance of fundamental data in decision-making.
